-
CA-074 Me in Lysosomal Cell Death Research
2026-09-07
CA-074 Me enables cell-permeable interrogation of cathepsin B during lysosomal membrane permeabilization, necroptosis, and apoptosis assays. Its strongest advantage is mechanistic placement: researchers can test whether cathepsin B is a downstream driver rather than merely a marker of lysosomal damage.
-
Calpain, BDNF/TrkB, and Offspring Cognition
2026-09-07
A 2025 Neuropharmacology study links maternal non-obstetric surgery during pregnancy to later offspring cognitive impairment through excessive calpain activity and suppression of hippocampal BDNF/TrkB signaling. Postnatal treatment with the calpain inhibitor MDL 28170 or the TrkB agonist 7,8-DHF partially rescued molecular, structural, and behavioral deficits, supporting calpain–TrkB dysregulation as a mechanistic target for neuroprotection research.
-
Omega-3 PUFAs Protect Against Cisplatin Nephrotoxicity
2026-09-05
The reference study shows that combined EPA and DHA protect mice and renal tubular epithelial cells from cisplatin-induced injury more effectively than either fatty acid alone. Its mechanistic contribution is the linkage of p62-Keap1-Nrf2 antioxidant signaling with MDM2-p53 apoptosis control, including reduced inflammation and chronic renal fibrosis after repeated CDDP exposure.
-
MLKL Polymerization and Lysosomal Membrane Permeabilization
2026-09-04
The reference study identifies lysosomal membrane permeabilization as a direct downstream consequence of MLKL polymerization during necroptosis. Its experiments place lysosomal cathepsin B release before plasma membrane rupture and show that cathepsin B inhibition or depletion can protect cells, providing a mechanistic framework for studying lysosomal protease activity in regulated cell death.
-
nor-NOHA Acetate: Arginase Research Workflows
2026-09-04
Build reproducible enzyme, cancer-cell, and vascular assays around nor-NOHA acetate, a reversible arginase inhibitor that redirects arginine metabolism. This workflow also shows how to position arginase experiments beside emerging lipid-driven immune-escape studies without overstating the evidence.
-
Cy3 TSA Fluorescence System Kit for Sparse Signals
2026-09-03
Learn how the Cy3 TSA Fluorescence System Kit can improve detection of sparse olfactory receptor signals while preserving spatial information. This article connects tyramide chemistry with the TRIM66 mechanism and practical assay design.
-
Bay 11-7821: From NF-κB Mechanism to Translation
2026-09-03
Bay 11-7821, also known as BAY 11-7082, is a versatile research tool for connecting IKK/NF-κB signaling with apoptosis, inflammasome biology, and translational models of inflammation and cancer. This article places the compound alongside emerging lactate-HMGB1 biology in sepsis and outlines a disciplined strategy for interpreting pharmacology across macrophage, endothelial, lymphoma, and tumor systems.
-
1-methyl Adenosine: Applied Quantification Workflows
2026-09-02
Build a practical 1-methyl Adenosine workflow that connects cell perturbation, RNA modification research, and targeted UHPLC–MS/MS. The approach emphasizes isomer resolution, matrix control, and biomarker-ready validation rather than relying on a single endpoint.
-
PEI-Modified Laminarin Nanoparticles as Vaccine Adjuvants
2026-09-02
The reference study developed polyethyleneimine-modified laminarin nanoparticles that combine a cationic polysaccharide carrier with ovalbumin to improve antigen uptake, dendritic-cell activation, lysosomal escape, and cross-presentation. Compared with aluminum adjuvant, the formulation produced stronger OVA-specific humoral and cellular immune responses, while also illustrating how polysaccharide functionalization can guide nanovaccine performance.
-
(+)-Bicuculline: Protocol and QC Guide
2026-09-01
This guide explains how to formulate and control (+)-Bicuculline, a GABAA receptor antagonist used to investigate inhibitory neurotransmission and related synaptic signaling. It is a research-use neuroscience tool only; formulation, storage, and interpretation should not be transferred to diagnostic, therapeutic, or clinical use.
-
OTUD3–SLC7A11 Axis in Sunitinib Resistance
2026-09-01
A 2025 Cancer Letters study identifies OTUD3-mediated deubiquitination of SLC7A11 as a mechanism that protects clear cell renal cell carcinoma from sunitinib-induced ferroptosis. The work links post-translational control of cystine transport to glutathione preservation, reduced lipid peroxidation, and treatment resistance, suggesting that OTUD3 inhibition could improve sunitinib response.
-
Hexamethonium Bromide for Autonomic Research
2026-08-31
Hexamethonium Bromide helps separate autonomic ganglia activity from vascular and cardiac effects in conscious cardiovascular models. This workflow translates sex-dependent angiotensin II hypertension findings into practical telemetry, solution-handling, control, and troubleshooting choices.
-
Carbapenemase Transmission in CREC Across Guangdong
2026-08-31
This study integrates carbapenemase gene localization, conjugative transfer, mobile genetic elements, strain relatedness, and hospital epidemiology in carbapenem-resistant Enterobacter cloacae from eight Guangdong teaching hospitals. Its central finding is that blaNDM-1 was common and frequently plasmid-associated, while the high transferability of carbapenemase-encoding genes underscores the need for mobility-aware surveillance and infection-control strategies.
-
ATRX Loss Sensitizes Glioma Cells to RTK Inhibitors
2026-08-30
The reference study used a drug screen to identify receptor tyrosine kinase and PDGFR inhibitors that preferentially affect ATRX-deficient high-grade glioma cells. Its combination experiments further showed that pairing these inhibitors with temozolomide produced pronounced toxicity, supporting ATRX status as a potentially useful biomarker for treatment-response interpretation.
-
Rucaparib and Spliceosome-Linked DNA Repair
2026-08-29
Rucaparib and AG-014699 provide a mechanistically rich platform for studying PARP1 inhibition, persistent DNA damage, and cancer-cell repair states. This article connects prostate cancer radiosensitization with emerging SmD2-dependent spliceosome biology in hepatocellular carcinoma to improve assay interpretation.